Based on internal projections for demand, the two companies have approved about $150 million in additional investments to ...

Legend Biotech is building a new $150 million manufacturing plant, with its partner Johnson & Johnson, with the goal of ...

Carvykti's success boosts Legend Biotech Corporation's Q4 2024 sales to $334M, solidifying market position. Click to find out ...

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how competitive Abecma will continue to be in the multiple myeloma space given an ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Legend Biotech’s (LEGN) shares have surged over 10% in the past few days, spurred by the company’s latest earnings report, thanks to ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 ...

Q4 2024 Earnings Call Transcript March 11, 2025 Legend Biotech Corporation beats earnings expectations. Reported EPS is $0.08 ...

However, Abecma has faced increasing competition in the multiple myeloma space, particularly from Johnson & Johnson and Legend Biotech’s BCMA CAR-T Carvykti (ciltacabtagene autoleucel).

Legend Biotech Corp (LEGN) reports a 110% increase in CARVYKTI sales, outlines expansion strategies, and anticipates ...